Correct me if I'm wrong but Eversana is not going to be a promoter of a BP acquisition.  Their expertise seems  to be in commercializing production for the client.  I view that as RVX not selling the store to a BP, but rather becoming a drug company which capitalizes on  efficient manufacturing, distribution and marketing  through the resources of Eversana. That is a much better outcome for investors because, in addition to a soaring sock price, it creates an ongoing huge revenue stream with dividends for many years. Once established other molecules can be pulled from the library and the business and science become self perpetuating.